Emerging Therapies: Autologous Derived Muscle Cells

Christopher E. Wolter, MD, presented “Emerging Therapies: Autologous Derived Muscle Cells” during the 1st International Functional and Reconstructive Urology Update on August 29, 2024, in Denver, Colorado.

How to cite: Wolter, Christopher E. “Emerging Therapies: Autologous Derived Muscle Cells.” August 29, 2024. Accessed Nov 2024. https://grandroundsinurology.com/emerging-therapies-autologous-derived-muscle-cells/

Emerging Therapies: Autologous Derived Muscle Cells – Summary

Christopher E. Wolter, MD, discusses using autologous muscle-derived cells as a promising treatment for stress urinary incontinence.

In this 7-minute talk, Dr. Wolter reviews the steps for the therapy procedure, which involves procuring muscle cells through a minimally invasive biopsy, expanding the cells in culture, and re-injecting them into the patient. He notes that stress urinary incontinence is considered an ideal target for this therapy.

Wolter shares the promising results from Initial studies, including a pilot trial in 2008. Later trials using higher doses of injected cells demonstrated even better outcomes. He also references the MYOCYTE trial, a large multicenter, multi-institutional randomized study, which suggested that patients with previous stress incontinence treatments, such as slings, respond better to the therapy.

About The 1st International Functional and Reconstructive Urology Update (IFRUU)

The International Functional and Reconstructive Urology Update is a multi-day meeting focused on functional and reconstructive urology (FRU). FRU is a rapidly expanding subspecialty with the vision to improve the lives of all patients with urinary disorders. The IFRUU conference aims to equip practitioners with the tools to manage patients with functional urologic disorders effectively. The inaugural IFRUU conference took place from August 28-30, 2024 in Denver, Colorado.

For further educational activities from this conference, visit our collection page.